{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:57:02Z","timestamp":1790823422916,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Head & Neck"],"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Technically resectable locally advanced head and neck squamous cell carcinoma may require highly morbid surgery. We evaluated short\u2010course neoadjuvant anlotinib plus paclitaxel\u2013cisplatin as a signal\u2010generating strategy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Twenty\u2010one patients received two 21\u2010day cycles in a prospective, single\u2010arm Phase II study. The primary endpoint was RECIST 1.1 objective response rate; pathological response and surgical extent were exploratory.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Objective response rate was 66.7% (14\/21; 95% CI, 43.0%\u201385.4%), meeting the prespecified activity criterion. Eight patients underwent surgery; all achieved R0 resection, 5\/8 achieved major pathological response, and 4\/8 underwent less extensive resection than initially planned. Documented adverse events were mainly Grade 1, including one Grade 1 hypertension controlled with levamlodipine and one Grade 2 primary\u2010tumor bleeding event; proteinuria was not systematically captured.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The regimen generated antitumor activity and surgical feasibility signals but does not establish anlotinib benefit beyond TP or functional preservation.<\/jats:p>\n \n Trial Registration:<\/jats:bold>\n Chinese Clinical Trial Registry: ChiCTR2100046440\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/hed.70501","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:06:41Z","timestamp":1790820401000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Anlotinib Plus Paclitaxel\u2013Cisplatin for Technically Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Prospective Single\u2010Arm Phase\n II<\/scp>\n Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5381-111X","authenticated-orcid":false,"given":"Ran","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng\u2010Jie","family":"Huang","sequence":"additional","affiliation":[{"name":"Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5371-6261","authenticated-orcid":false,"given":"Zhen\u2010Hua","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0859-6738","authenticated-orcid":false,"given":"Li\u2010Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3306-7564","authenticated-orcid":false,"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u2010Fang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China Mianyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_2_11_2_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung H.","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/S0140-6736(21)01550-6","article-title":"Head and Neck Cancer","volume":"398","author":"Mody M. D.","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous Cell Carcinoma of the Oral Cavity, Larynx, Oropharynx and Hypopharynx: EHNS\u2010ESMO\u2010ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow\u2010Up","volume":"31","author":"Machiels J. P.","year":"2020","journal-title":"Annals of Oncology"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","article-title":"NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2025","volume":"23","author":"Colevas A. D.","year":"2025","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/jnci\/88.13.890","article-title":"Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial","volume":"88","author":"Lefebvre J. L.","year":"1996","journal-title":"Journal of the National Cancer Institute"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer","volume":"349","author":"Forastiere A. A.","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long\u2010Term Results of RTOG 91\u201011: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer","volume":"31","author":"Forastiere A. A.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.2005.01.2047","article-title":"Single\u2010Cycle Induction Chemotherapy Selects Patients With Advanced Laryngeal Cancer for Combined Chemoradiation: A New Treatment Paradigm","volume":"24","author":"Urba S.","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00455-025-10888-2","article-title":"Evaluation of Swallowing Function and Aspiration in Newly Diagnosed Head and Neck Cancer Patients","volume":"41","author":"Cheng P. C.","year":"2026","journal-title":"Dysphagia"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer","volume":"357","author":"Vermorken J. B.","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2003.06.146","article-title":"Primary Chemotherapy in Resectable Oral Cavity Squamous Cell Cancer: A Randomized Controlled Trial","volume":"21","author":"Licitra L.","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane\u2010Cisplatin\u2010Fluorouracil as Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta\u2010Analysis of the Meta\u2010Analysis of Chemotherapy in Head and Neck Cancer Group","volume":"31","author":"Blanchard P.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta\u2010Analysis of Chemotherapy in Head and Neck Cancer (MACH\u2010NC): An Update on 93 Randomised Trials and 17,346 Patients","volume":"92","author":"Pignon J. P.","year":"2009","journal-title":"Radiotherapy and Oncology"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"900903","DOI":"10.3389\/fonc.2022.900903","article-title":"Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers","volume":"12","author":"Boguszewicz L.","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy Plus Cetuximab for Squamous\u2010Cell Carcinoma of the Head and Neck","volume":"354","author":"Bonner J. A.","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum\u2010Based Chemotherapy Plus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken J. B.","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous\u2010Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris R. L.","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head\u2010And\u2010Neck Squamous Cell Carcinoma (KEYNOTE\u2010040): A Randomised, Open\u2010Label, Phase 3 Study","volume":"393","author":"Cohen E. E. W.","year":"2019","journal-title":"Lancet"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE\u2010048): A Randomised, Open\u2010Label, Phase 3 Study","volume":"394","author":"Burtness B.","year":"2019","journal-title":"Lancet"},{"key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Squamous Cell Carcinoma of the Head and Neck (HNSCC)","volume":"7","author":"Cohen E. E. W.","year":"2019","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus\u2010Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial","volume":"26","author":"Uppaluri R.","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open\u2010Label Randomized Clinical Trial","volume":"6","author":"Schoenfeld J. D.","year":"2020","journal-title":"JAMA Oncology"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local\u2010Regionally Advanced Head and Neck Squamous Cell Carcinoma","volume":"28","author":"Wise\u2010Draper T. M.","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jamaoto.2025.1707","article-title":"Pathologic Treatment Effect and Survival in HPV\u2010Negative HNSCC Following Neoadjuvant Nivolumab","volume":"151","author":"Moroco A. E.","year":"2025","journal-title":"JAMA Otolaryngology. Head & Neck Surgery"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"1799437","DOI":"10.3389\/fonc.2026.1799437","article-title":"Perioperative Immunotherapy in Resectable HNSCC: Biological Rationale to Practical Multidisciplinary Implementation","volume":"16","author":"Bila M.","year":"2026","journal-title":"Frontiers in Oncology"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/cac2.70006","article-title":"Neoadjuvant Chemotherapy Plus Anlotinib in the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Pilot Phase II Trial","volume":"45","author":"He Q.","year":"2025","journal-title":"Cancer Commun"},{"key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/odi.15290","article-title":"Real\u2010World Study of Later\u2010Line Anlotinib in Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","volume":"31","author":"Ju H.","year":"2025","journal-title":"Oral Diseases"},{"key":"e_1_2_11_29_1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/aps.2017.199","article-title":"Pharmacokinetics and Disposition of Anlotinib, an Oral Tyrosine Kinase Inhibitor, in Experimental Animal Species","volume":"39","author":"Zhong C. C.","year":"2018","journal-title":"Acta Pharmacologica Sinica"},{"key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"937924","DOI":"10.3389\/fimmu.2022.937924","article-title":"Effective Low\u2010Dose Anlotinib Induces Long\u2010Term Tumor Vascular Normalization and Improves Anti\u2010PD\u20101 Therapy","volume":"13","author":"Fan P.","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12935-020-01721-x","article-title":"Anlotinib as a Promising Inhibitor on Tumor Growth of Oral Squamous Cell Carcinoma Through Cell Apoptosis and Mitotic Catastrophe","volume":"21","author":"Deng Z.","year":"2021","journal-title":"Cancer Cell International"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jgg.2021.06.014","article-title":"Suppressed Mitochondrial Respiration via NOX5\u2010Mediated Redox Imbalance Contributes to the Antitumor Activity of Anlotinib in Oral Squamous Cell Carcinoma","volume":"48","author":"Huang Z.","year":"2021","journal-title":"Journal of Genetics and Genomics"},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/odi.14404","article-title":"SOD2 Confers Anlotinib Resistance via Regulation of Mitochondrial Damage in OSCC","volume":"30","author":"Li S.","year":"2024","journal-title":"Oral Diseases"},{"key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten Years of Anti\u2010Vascular Endothelial Growth Factor Therapy","volume":"15","author":"Ferrara N.","year":"2016","journal-title":"Nature Reviews. Drug Discovery"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing Tumor Vasculature With Anti\u2010Angiogenic Therapy: A New Paradigm for Combination Therapy","volume":"7","author":"Jain R. K.","year":"2001","journal-title":"Nature Medicine"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of Anlotinib as a Third\u2010Line or Further Treatment on Overall Survival of Patients With Advanced Non\u2010Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","volume":"4","author":"Han B.","year":"2018","journal-title":"JAMA Oncology"},{"key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft\u2010Tissue Sarcoma","volume":"24","author":"Chi Y.","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline, Version 1.1","volume":"45","author":"Eisenhauer E. A.","year":"2009","journal-title":"European Journal of Cancer"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological Response After Neoadjuvant Chemotherapy in Resectable Non\u2010Small\u2010Cell Lung Cancers: Proposal for the Use of Major Pathological Response as a Surrogate Endpoint","volume":"15","author":"Hellmann M. D.","year":"2014","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic Features of Response to Neoadjuvant Anti\u2010PD\u20101 in Resected Non\u2010Small\u2010Cell Lung Carcinoma: A Proposal for Quantitative Immune\u2010Related Pathologic Response Criteria (irPRC)","volume":"29","author":"Cottrell T. R.","year":"2018","journal-title":"Annals of Oncology"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD\u20101 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde P. M.","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer","volume":"386","author":"Forde P. M.","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_43_1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ\u2010C30: A Quality\u2010Of\u2010Life Instrument for Use in International Clinical Trials in Oncology","volume":"85","author":"Aaronson N. K.","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"key":"e_1_2_11_44_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/000348940811701210","article-title":"Validity and Reliability of the Eating Assessment Tool (EAT\u201010)","volume":"117","author":"Belafsky P. C.","year":"2008","journal-title":"Annals of Otology, Rhinology, and Laryngology"},{"key":"e_1_2_11_45_1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.apmr.2004.11.049","article-title":"Initial Psychometric Assessment of a Functional Oral Intake Scale for Dysphagia in Stroke Patients","volume":"86","author":"Crary M. A.","year":"2005","journal-title":"Archives of Physical Medicine and Rehabilitation"}],"container-title":["Head & Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70501","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hed.70501","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.70501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:06:48Z","timestamp":1790820408000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.70501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":44,"alternative-id":["10.1002\/hed.70501"],"URL":"https:\/\/doi.org\/10.1002\/hed.70501","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2026-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hed.70501"}}